

KEVIN JOHNSON, CEO ISABELLE MADDOCK, CFO STEPHEN EASTON, COO

APRIL 2024

DISCLAIMER

The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the "Presentation") have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). Reliance upon this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. If any person is in any doubt as to the contents of this Presentation, they should seek independent advice from a person who is authorised for the purposes of FSMA and who specialises in advising on investments of this kind. This Presentation is being supplied to you solely for your information and does not purport to contain all information that may be required to evaluate Surface Transforms plot (the "Company"). This Presentation has been prepared by, and is the sole responsibility of, the Company have taken all reasonable care to ensure that the facts stated herein are true to the best of their knowledge, information and belief.

This Presentation does not constitute, or form part of, an admission document, listing particulars, a prospectus or a circular relating to the Company, nor does it constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company nor shall it or any part of it, or the fact of its distribution, form the basis of, or be relied upon in connection with, or act as any inducement to enter into any contract. Any investment in shares in the Company should only be made by you on the basis of definitive documentation in final form (which may contain different information from the information contained in this Presentation), and you own judgment as to the merits of the suitability of the shares for your purposes, having taken all such professional advice you consider necessary or appropriate in the circumstances.

No reliance may be placed for any purpose whatsoever on the information or opinions contained in this Presentation or on its completeness, accuracy or fairness thereof, nor is any responsibility accepted for any errors, misstatements in, or omission from, this Presentation or any direct or consequential loss however arising from any use of, or reliance on, this Presentation or otherwise in connection with it.

By accepting this Presentation you confirm, represent and warrant that you have consented to receive inside information (as defined in the Criminal Justice Act 1993 and the Financial Services and Markets Act 2000 (as amended)), and you agree not to deal in any securities of the Company until such time as such inside information has been made public and until such time that the Placing has been publicly announced by the Company.

This Presentation may not be reproduced or redistributed, in whole or in part, to any other person, or published, in whole or in part, for any purpose without the prior consent of the Company. The contents of this Presentation are confidential and are subject to updating, completion, revision, further verification and amendment without notice.

The Presentation is being distributed on request only to, and is directed at, authorised persons or exempt persons within the meaning of FSMA or any order made thereunder or to those persons falling within the following articles of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Financial Promotion Order"); Investment Professionals (as defined in Article 19(5)) or are eligible counterparties within the meaning given in COBS 3.6.1 of the FSA Handbook as at 1 November 2007; High Net Worth Companies (as defined in Article 49(2)) and Members or Creditors of the Company (as defined in Article 43(2)) as well as persons to who distribution may otherwise lawfully be made (all such persons being "Relevant Persons"). Any person who is not a Relevant Person should not rely on this Presentation on take any action upon it but should return it immediately to the Company. This Presentation is exempt from the general restriction in section 21 of FSMA relating to the communication of invitations or inducements to engage in investment activity on the grounds that it is made only to certain categories of persons.

Neither this Presentation nor any copy of it should be distributed, directly or indirectly, by any means (including electronic transmission) to any persons with addresses in the United States of America (or any of its territories or possessions) (together, the "US"), Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any legal or regulatory requirement. The recipients should inform themselves about and observe any such requirements or relationship. The Company's ordinary shares have not been, and are not expected to be, registered under the United States Securities Act 1933, as amended, (the "US Securities Act") or under the securities laws of any other jurisdiction, and are not being offered or sold, directly or indirectly, within or into the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of south Africa, or to penefit of, any US persons or any national, citizen or resident of the US, Australia, Canada, Japan, the Republic of Ireland or the Republic of South Africa, unless such of any other applicable securities laws.

This Presentation or documents referred to in it contain forward-looking statements. These statements relate to the future prospects developments and business strategies of the Company and its subsidiaries (the "Group"). Forward-looking statements are identified by the use of such terms as "believe", "could", "envisage", "estimate", "potential", "intend", "may", "plan", "will" or the negative of those, variations or comparable expressions, including references to assumptions. The forward-looking statements contained in this Presentation are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Group's actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward-looking statements. These forward-looking statements speak only as at the date of this Presentation. The Company is under no obligation to, and expressly disclaims any intention to, update or revise such forward-looking statements, estimates or projections.

By accepting receipt of, attending any delivery of, or electronically accessing, the Presentation, you agree to be bound by the above limitations and conditions and, in particular, you represent, warrant and undertake to the Company that: (i) you are a Relevant Person (as defined above); (ii) you will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose and (iii) you have read and agree to comply with the contents of this disclaimer.

PRESENTATION TEAM



DR KEVIN JOHNSON CHIEF EXECUTIVE OFFICER Kevin has a doctorate in Chemistry from the University of Liverpool and an MBA from Manchester Business School. He has spent six years in product development for the chemical industry and has a broad experience with OEM multinationals in the area of new technology development for automotive and aerospace industries. Previously he worked for Avecia, formerly AstraZeneca. Kevin joined the company in 2005 and the board as CEO in 2006. Kevin is one of the world's foremost authorities on carbon ceramics and has significant experience of strategic management in the automotive sector.



Isabelle is a fellow of the Chartered Institute of Management Accountants with over 30 years' experience. She joined Surface Transforms from James Cropper plc where she was Chief Financial Officer for 9 years. Prior to this she has held a number of financial roles across a variety of sectors covering manufacturing (Angus Fire Amour, Ethicon Ltd) software (Adobe Systems Europe Ltd), retail (Landmark Ltd), PFI (Haden Building Management Ltd) and publishing (CGP Ltd). Isabelle is Chair of the CBI's Economic Growth Board and joined the Board of Surface Transforms in September 2023.



Stephen has over 26 years of experience and joins the organisation from SGL Carbon, a €1bn revenue global graphite and fibre manufacturing company, where he was Managing Director for their UK operations. During his 16-year tenure he held various leadership positions both in the UK and US, specialising in carbon and oxidised fibre. Prior to this, he worked in a variety of different senior operational roles within the manufacturing sector. He holds an honours degree in Manufacturing Engineering & Management from the University of Dundee. Stephen joined Surface Transforms in September 2023.



ABOUT SURFACE TRANSFORMS

Manufactures carbon-ceramic brake discs for automotive




Automotive brake discs

- Brake components installed on all four wheels of the car
- Key safety and performance feature of the vehicle
- Integrated complex system
- · Braking achieved by the caliper pressing the brake pads against the brake disc
- · Carbon ceramic discs are a replacement technology for grey cast iron







A leading supplier of carbon ceramic brake discs

- Premium product with proprietary technology¹
- £2b/yr addressable market²
- Advanced manufacturer with significant expansion opportunity³
- High growth with contracted models worth £390m and PCP of £300m⁴
- 5-year capital expansion plan well underway to deliver £150m capacity revenue for 2027 to support demand from contracts and PCP⁵
- Installing £50m/yr sales capacity in Q4 2024




1 In terms of heat management and lifetime

2 This is based on the directors' expectations, their understanding of the relevant OEMs production plans and estimated demand for discs 3 Directors' belief based on the proprietary technology of the Company and current customer demands and prospective contract pipeline 4 This is based on the directors' expectations, their understanding of the relevant OEMs production plans and estimated demand for discs ilifetime revenue from the company's contract with OEM 10 which is anticipated to be entered into following the company's recent nomination as OEM 10's tier one supplier of a carbon ceramic brake discs 5 Based on management's estimates of sales proceeds from expected production volumes

CURRENT STATUS & STRATEGY Ambition to reach £100m/yr sales in next 5 years¹

Business KPIs





production

performance

risks mitigated

Increasing

expanding

Equipment

•


1 The Directors believe that based on existing customer contracts and PCPs, the current capacity will not provide the required production capacity to meet demands from OEMs

2 Quarterly revenues outlook for 2024 and 2025 based on management's low-case estimates.

3 Current quarter management estimate

4 The Company and Liverpool City Region's Urban Development Fund (which is part funded by the ERDF) have agreed revised financial covenants for the Loan Facility agreement, with revised banking documentation currently being prepared. Management's low-case estimates include approximately £10.45m total use of the Loan Facility by the end of the two year drawdown period ending 31 December 2025

CASH UTILISATION 6 months to the end of Q1 2024 comparison to Optimus





PROJECT BUMBLEBEE

Proposed £6.5m placing with open offer

- Supports immediate working capital requirements existing operations and scale up
- Building effective manufacturing capacity for positive EBITDA in the near term
 - Improving yield
 - 5 contracts in multi-year revenue generation phase
 - Advancing cost reduction plan
- Phase 2 manufacturing capacity of £50m/yr in 2024 and £75m/yr in 2025
 - Debt finance in place
 - Booked to existing contracts¹
 - Lifetime contracts value over £390m²
 - Contracts awarded total £79m/yr revenue



MANUFACTURING CAPACITY

Increasing capacity capability and capacity resilience

Capacity Revenue Capacity in place - supports 'in series' contracts £20m/yr PHASE 1 Installed and in production Improving effectiveness, with opportunity to deliver more than £20m/yr • £14m¹ investment capacity expansion - fully booked to current contract awards £50m/yr capacity support 2024 demand & establish some capacity resilience² £50m/yr • Available for production in 2024 ٠ £75m/yr required for capacity resilience and growth in 2025 Remaining equipment defined with installation in 2025 ٠ £75m/yr Available for production in 2025 ٠ Supported by debt finance facility • £30m investment capacity planning – required for 2026/27 Required to support contract awards and PCP³ • Land and building lease complete to support expansion plans • Equipment and process technology in development ٠

1 This figure is rounded up and includes a 10% contingency

2 These figures are based on management's estimates of sales proceeds from expected production volumes

3 Based on the directors' expectations, their understanding of the relevant OEMs production plans and estimated demand for discs

BUSINESS DEVELOPMENT KPIS

Sustainable growth with strong order book and prospective contract pipeline (PCP)¹

- Strong and growing number of contract awards providing sustainable, high growth over next 5 years ٠
- Substantial number of follow on contracts leveraging ST product technology and customer relationships
- Increasing number of contracts in series production driving revenue growth¹
- Stable customer base working closely with ST to support capacity expansion and growth
- Large lifetime contract value of $\pm 390 \text{ m}^1$, providing contract revenues of $\pm 79 \text{ m/yr}^1$
- Significant PCP of £300m¹, offering additional £50m/yr¹ revenue, the majority of which is follow on contract opportunity ٠

OEM 5	German car manufacturer				
OEM 6	British performance car manufacturer				
OEM 7	Swedish performance car manufacturer				
OEM 8	Global car manufacturer				
OEM 9	New car manufacturer				
OEM 10	US car manufacturer				
Other OEMs	Engaged in numerous sourcing discussions ²				


Contract Awards				Follow on contra				
	8	11	12			4	4	
_	2021	2022	2023			2021	2022	20
Lifetime contract value ¹ £'m			Contracts revenue/yr¹£'m					
		c200	£390			(av	rerage)	£

2023


2021


2022

2023



2021







1 This is based on the directors' expectations, their understanding of the relevant OEMs production plans and an assumed disc demand 2 This is based on the directors' confirmation that the Company has engaged in sourcing discussions with other OEMS

2021

2022

INVESTMENT SUMMARY

Building effective manufacturing capacity for positive EBITDA in the near term

- 5 contracts in multi-year revenue generation phase
- Improving yield
- Advancing cost reduction plan

Phase 2 manufacturing capacity of £50m/yr in 2024 and £75m/yr in 2025

- Debt finance in place
- Booked to existing contracts¹
- Lifetime contracts value over £390m²
- Contracts awarded total £79m/yr revenue

Contracts and PCP requires Phase 3 £150m/yr capacity

- Required for anticipated demand and manufacturing resilience
- PCP opportunity of additional £50m/yr² revenue



T this is based on management's estimates of sales proceeds from expected production volumes 2 This is based on the directors' expectations, their understanding of the relevant OEMs production plans and estimated demand for discs and it takes into account the expected lifetime revenue from the company's contract with OEM IO which is anticipated to be entered into following the company's recent nomination as OEM 10's tier one supplier of a carbon ceramic brake discs